About Us

Edanz was founded in Japan in 1995, and has been providing high quality and cost effective medical and scientific editing, rewriting and publication guidance to the academic and research communities ever since. Edanz joined M3 Group (Tokyo Stock Exchange First Section -securities code 2413) in 2019.

Edanz Team

Koji Yamashita

Koji Yamashita

CEO & Director

Koji Yamashita joined Edanz in January 2016 as Group CEO and board member. Koji joined Edanz from SpringerNature where he was Japan President and Managing Director as well as the APAC Regional Sales Director for Springer Healthcare, a leading global provider of medical communications services. Koji has a wealth of experience in the medical communications and publication industry.

Tom da Costa

Tom da Costa

Director & Board member

Tom da Costa graduated from the University of Oxford in 2000 where he specialized in ancient languages. His international career includes positions in the city of London, Sydney and Japan. Tom oversees the medical writing division, and is a member of the Edanz Group management team.

Tom is a member of ISMPP.

Daniel McGowan, PhD, CMPP

Daniel McGowan, PhD, CMPP

Director & Board member

Dr Daniel McGowan, PhD Molecular Neuroscience, was an Associate Editor of Nature Reviews Neuroscience, before joining the Edanz Group in 2006. Prior to working in the publishing industry, Dr McGowan was a Senior Scientist at the University of Cambridge, UK and a Marie Curie Research Fellow at the Babraham Institute, also in Cambridge. He has more than ten years of post-doctoral and post-graduate laboratory experience in the areas of neurodegenerative diseases, molecular and cellular biology, protein biochemistry, proteomics and genomics.

Daniel is a member of ISMPP and is a Certified Medical Publications Professional.

Mayako Ikeda

Mayako Ikeda

Senior Solutions Manager

Mayako Ikeda joined Edanz in 2020 to lead the Solutions Team. Mayako is an experienced professional, with 16 years in the pharmaceutical industry, leading global teams at Springer Healthcare and IQVIA.

Her focus is on strategic medical communications solutions, scientific content development, specialized training programs, and targeted medical education initiatives.

Hikari Wilson, BPharm

Hikari Wilson, BPharm

MSL and Project Manager

Hikari earned her BPharm at Yokohama University of Pharmacy in 2014. Her bachelor research involved investigating a new approach to cranial nerve disease. After graduation, Hikari worked for the Tokyo office of the global contract research organization Parexel International, where she gained clinical development experience in virology, dermatology and oncology.

Hikari is a member of ISMPP.

NiNi MoeMyint, BSc, PhD

NiNi MoeMyint, BSc, PhD

Project Manager

NiNi graduated with a BSc Hons (1st) in Medical Biochemistry from University of Leicester in 2013 before undertaking her postgraduate research at Leicester Cancer Research Centre (University of Leicester) and earning a doctorate in 2018. Her research interest was in the field of cancer liquid biopsy and her thesis investigated circulating cell-free tumour DNA as a potential biomarker for early detection and chemoprevention of colorectal cancer. She is knowledgeable in the areas of cancer biology, metabolic regulations, signal transduction, genetics, and biochemical mechanisms of diseases. She has research experience in both in vivo and in vitro studies with technical expertise in various PCR methods (qPCR, ddPCR), mutation detection, DNA sequencing, assay development, cell culture, western blotting, histopathology, and sample processing. Ni Ni joined the Edanz Medical Writing team in 2018.

Mary Richardson, MSc, CMPP

Mary Richardson, MSc, CMPP

Project Manager

Mary earned her BSc (Hons) in biochemistry at the University of Winnipeg in 2008. Upon graduating and gaining experience in a federal research lab, Mary pursued graduate studies as a MEXT scholar at the University of Tohoku, Japan, where she earned her MSc in chemistry in 2014. Her Masters research involved investigating molecular mechanisms related to the subcellular localization of IPAS, a dual-function protein expressed in neural cells and implicated in familial Parkinson’s disease. Mary is well-versed in many areas of biochemistry, including enzymology, signal transduction, genetics, and immunology. She has experience in bacterial and mammalian cell culture, DNA sequencing, recombinant DNA techniques (vector construction and primer design), PCR, electrophoresis, western blotting, and immunoprecipitation.

Mary is a member of ISMPP and is a Certified Medical Publications Professional.

James Graham, MSc, PhD

James Graham, MSc, PhD

Project Manager

After completing an MSc in Biomedical Sciences, Dr Graham obtained his PhD in Biochemistry in 2009. As a post-doctoral research scientist at The Roslin Institute in Edinburgh, Dr Graham developed an analytical in vitro assay that would analyze the risk factor of newly discovered animal prion diseases to infect humans. He then moved to the German Center for Neurodegenerative Diseases in Bonn, Germany, where he worked on the novel concept of alpha-synuclein strains in Parkinson’s disease and other synucleinopathies. Dr Graham was appointed to the Executive Committee of the Australasian Medical Writers Association (AMWA) in August 2016.

Abeer Fadl, BA, MA, MPP, CMPP

Abeer Fadl, BA, MA, MPP, CMPP

Assistant Project Manager & Medical Copy Editor

Abeer specializes in strategic communications and project management. As part of the Edanz Medical Writing team, her roles include project management, process development, communications, and medical writer and expert reviewer onboarding and management.

Abeer is a member of ISMPP and is a Certified Medical Publications Professional.

Hideki Maikuma, MSc

Hideki Maikuma, MSc

Project Manager

Hideki earned his MSc in pharmacology from Nagoya City University in 1998. After obtaining his degree, Hideki worked for several global pharmaceutical companies, where he gained extensive knowledge in clinical development. Hideki has 15 years’ experience in medical and pharmaceutical translation and medical writing, and his areas of expertise include clinical studies, regulatory affairs, post-marketing surveillance, and manuscript development.

Suzi Barboza-Pacheco, BSc

Suzi Barboza-Pacheco, BSc

Medical Copy Editor

Suzi earned her BSc in biochemistry and molecular biology at Oklahoma State University in 2017. She worked in various research labs and developed independent projects researching novel therapies for Alzheimer’s disease and methods for applying statistical algorithms for crop quality prediction in Maize. After graduating, she worked as a data analyst for LexisNexis where she provided technical expertise and proofread technical and legal documents. Suzi joined the Edanz Medical Writing team in 2018.

Medical writers and reviewers

The Edanz medical writing team comprises former academics and industry researchers with excellent communication skills. Many have previously performed in-house medical writing duties within pharma or worked for medical communications agencies.

Edanz writers work as a team on each project: one lead writer and internal reviewer. Each project will also have an independent clinical reviewer. The project manager will coordinate this team to get the maximum benefit from each person’s expertise. Below are just a few of the reviewers who work on Edanz projects.

Dr Sally Mitchell, Senior Medical Writer

1996 – PhD in Molecular Biology and Biochemistry, University of Leicester

Profile

After receiving her PhD, Dr Mitchell spent more than 10 years as a researcher and pharmacy lecturer in universities around Europe before moving into the medical communications field. During her time in academia, she authored more than a dozen articles published in international journals, and presented her work at many international conferences. Since becoming involved in medical writing more than 13 years ago, Dr Mitchell has worked on global and national accounts for many of the top pharmaceutical companies, and also directly with academic and clinical researchers. She has been a contributor to the development of more than 100 manuscripts, many published in top-tier journals. Dr Mitchell has a wide range of therapeutic experience from both approved and developmental products, with specific strengths in oncology, neurology, pain, anti-infectives, and cardiovascular disease.